top of page

3 Acquired Biotechs Held by Hedge Funds & BPIQ Model Portfolios

  • 3 days ago
  • 2 min read

Updated: 2 days ago

Summary

  • Before the deals were announced, $TERN, $CNTA, and $RAPT were each held by multiple biotech-focused hedge funds tracked by BPIQ and appeared as immediately prior positions in BPIQ model portfolios.

  • At year-end 2025, BPIQ recorded 34 fund-ticker positions across the three companies. TERN was held by 10 biotech-focused hedge funds tracked by BPIQ, while CNTA and RAPT were each held by 12. Their prior BPIQ model-portfolio target allocations ranged from 3.8% to 7.0%.

  • The transactions produced different stock outcomes, from large announcement-day gains to a takeover that followed a major pre-deal run-up.


Using BPIQ hedge fund, model portfolio, and M&A data, we reviewed Q4 2025, the last full reporting quarter before each acquisition announcement, together with the model-portfolio positions recorded before the transactions closed.


BPIQ table of Q4 2025 pre-deal hedge fund holdings for Terns, Centessa, and RAPT, with M&A dates, reported values, deal terms, and stock context.

The overlap also extended across targets. ADAR1 held all three companies at year-end. Orbimed, Deep Track, and Ikarian held both TERN and RAPT, while TCG Crossover, RTW, and Perceptive held both CNTA and RAPT.



Prior BPIQ Model-Portfolio Positions

The latest BPIQ portfolio feed records $TERN, $CNTA, and $RAPT as immediately prior model-portfolio positions that were later removed following acquisition activity.


Their prior target allocations ranged from 3.8% to 7.0%. Together with the hedge fund data, this shows that the same three companies appeared across both BPIQ research lenses before their acquisitions closed.


BPIQ table showing prior model-portfolio positions for Terns, Centessa, and RAPT, alongside M&A announcement and closing dates and stock-market outcomes.

What This Means

BPIQ's model portfolios are built from structured interpretations of biotech hedge fund consensus. Neither hedge fund ownership nor portfolio inclusion is designed to predict takeovers. Still, these cases show that several independent specialist investors and BPIQ's portfolio methodology had identified value in the same companies before strategic buyers announced their deals.


CNTA and RAPT delivered large announcement-day moves. TERN was different: much of its re-rating occurred before Merck's bid, so the final takeover premium captured only the last part of the broader pre-acquisition move.


M&A is only one possible outcome. Clinical data, regulatory progress, financing, partnerships, and commercial execution can also drive returns. For biopharma investors, the analysis is more useful when institutional positioning, model-portfolio inclusion, and the full stock-price path are evaluated together rather than through a headline premium alone.


See the current targets

Elite and APEX subscribers can view holdings and target allocations on BPIQ's Model Portfolios page


BPIQ End-of-July Watchlist Sale banner, July 27 to August 2: 40% off APEX Annual and 50% off Elite Annual, featuring the Catalyst Screener, PDUFA Calendar, and Big Mover Stocks.

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.


Article history:

First published 7/27/26 RF, AV

 
 
 
bottom of page